Double the Brain Power

. . . CV Therapeutics (Nasdaq: CVTX) and Pharmacopeia Drug Discovery, Inc. (Nasdaq: PCOP) have entered into a drug discovery and development collaboration with the goal of developing novel therapeutics. The partnership brings together CV's molecular cardiology expertise and Pharmacopeia's cutting-edge drug discovery technology to potentially speed the discovery and development of new therapies for cardiovascular disease.

From: www.SmallcapRecap.com

New Kidney Cancer Drug

. . . Kidney cancer breakthrough. Phase III clinical trial data showed that a new drug, BAY 43-9006, developed by Onyxx (NasdaqNM:ONXX) and its partner Bayer, is able to slow the spread of advanced kidney cancer. Based on the strong data, the drug may be eligible for accelerated approval by the FDA, which can speed up the approval approval from two or more years to only one year.

From: www.SmallcapRecap.com

Behind the L-3 Story

. . . Cramer says buy L-3 Communications (NYSE: LLL) hand over fist (3/21). Shares of L-3 dived on a story in the NY Times about an FBI investigation. CEO Frank Lanza went on Jim Cramer's show Mad Money to talk about the situation. It was a story that Bloomberg covered a couple of months ago and apparently there isn't much of a story there. Cramer enthusiastically backed L-3 and sure enough, L-3 shares rose in after-hours trading.

A New Natural, Zero-Calorie Sweetner

. . . Sweet spot. This past weekend at the Natural Products Expo in Anaheim, CA, Health Sciences Group (OTCBB:HESG), introduced a new natural, zero-calorie sweetner. According to the company, Shugr(TM) is the world's first natural sweetener that has zero calories, tastes and cooks like sugar, is tooth friendly, diabetic safe, and has no aftertaste. It is not made from aspartame, cane sugar, acesulfame-K, saccharin, high fructose corn syrup, neotame, fructose, honey or stevia. Instead, it is made from sugars that occur naturally in fruits, vegetables, corn and dairy products.

From: www.Smallcaprecap.com